Pfizer backs out of $160B Allergan deal; White House scores victory
Pfizer's backed out of that historic $160 billion merger with Allergan, thanks to Washington toughening up on corporate inversions.
corporate inversion
Pfizer's backed out of that historic $160 billion merger with Allergan, thanks to Washington toughening up on corporate inversions.